Alnylam Pharmaceuticals Inc (ALNY)vsConduit Pharmaceuticals Inc. (CDT)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CDT
Conduit Pharmaceuticals Inc.
$0.49
+1.60%
HEALTHCARE · Cap: $1.78M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
CDT
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for CDT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CDT
The strongest argument for CDT centers on Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CDT
The primary concerns for CDT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CDT is a value play — different risk/reward profiles.
CDT carries more volatility with a beta of 1.81 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
CDT generates stronger free cash flow (181M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 27/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Conduit Pharmaceuticals Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Conduit Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in oncology and rare diseases. Utilizing its proprietary drug delivery platform, Conduit aims to significantly enhance the efficacy and safety of existing therapies while minimizing side effects to improve patient outcomes. Backed by a seasoned management team with extensive experience in biopharmaceutical development, the company is well-positioned to generate strategic partnerships that can accelerate the growth of its promising product pipeline. With a commitment to pioneering therapeutic solutions, Conduit Pharmaceuticals is poised to become a vital contributor to advancements in healthcare.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?